Open AccessPharmacotherapy of specific and unspecific respiratory infections
Author(s) -
Ya. M. Balabanova,
S. I. Kuznetsov,
K. Grem,
Ivan Fedorin,
M. Raddy,
Rifat Atun,
R. Koker,
F. Drobnevsky,
А. В. Жестков,
N. N. Kryukov
Publication year - 2005
Publication title -
pulʹmonologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.126
H-Index - 6
eISSN - 2541-9617
pISSN - 0869-0189
DOI - 10.18093/0869-0189-2005-0-1-87-92
Subject(s) - medicine , bronchitis , chronic bronchitis , intensive care medicine , drug , tuberculosis , pneumonia , rifampicin , pharmacotherapy , antimicrobial , respiratory tract infections , drug resistance , respiratory system , pharmacology , pathology , chemistry , organic chemistry , microbiology and biotechnology , biology
Irrational administration of antimicrobials, incorrect regimens and dosing provide occurrence of adverse effects with minimal therapeutic results and development of drug resistance including anti-tuberculosis drugs. The study was designed to detect information sources on drug therapy used by general practitioners and TB specialists, to establish stereotypical models of antibacterial drug administration in prevalent upper and lower airway diseases at the Samara region and to substantiate the supposition about unreasonable empiric administration of anti-tuberculosis drugs in a respiratory patient without microbiological confirmation as a probable cause of drug resistant tuberculosis. A cross-sectional study based on a special questionnaire was performed in 425 general practitioners in primary care facilities, hospitals and in TB specialists at the Samara region. The questionnaire contained several clinical situations and their solving and the respondents should choose the most suitable ones. Results demonstrated that majority of the practitioners (80 %, or 340 / 425 cases) widely use advertising information regarding antimicrobials. Several doctors (1.7 %) chose antibacterial drugs to treat acute respiratory viral infection, 0.8 to 1.6 % of doctors certainly decided to administer anti-tuberculotics in non-TB respiratory diseases such as acute bronchitis, chronic obstructive pulmonary disease, communityacquired pneumonia and acute tonsillitis, and approximately one fifth of the practitioners thought to administer antituberculotics in these diseases (18.4 % (78 / 425) – rifampicin, 21.2 % (90 / 425) – isoniasid).